Tetragenetics names new CEO
Cacciuttolo was MedImmune, Medarex Technical Operations vice president, and was recently president and CEO of PERCIVIA. The company also appointed Ben Machielse and Robert Gailus to the Board
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).